US Stock MarketDetailed Quotes

IOVA Iovance Biotherapeutics

Watchlist
  • 9.320
  • -0.080-0.85%
Close Nov 29 13:00 ET
  • 9.350
  • +0.030+0.32%
Post 17:02 ET
2.84BMarket Cap-6297P/E (TTM)

About Iovance Biotherapeutics Company

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Company Profile

SymbolIOVA
Company NameIovance Biotherapeutics
Listing DateFeb 26, 2015
Founded2007
CEOMr. Frederick G. Vogt, J.D.,PhD
MarketNASDAQ
Employees557
Fiscal Year Ends12-31
Address825 Industrial Road,Suite 400,4th Floor
CitySan Carlos
ProvinceCalifornia
CountryUnited States of America
Zip Code94070
Phone1-650-260-7120
Websitehttp://www.iovance.com

Company Executives

  • Name
  • Position
  • Salary
  • Frederick G. Vogt, J.D.,PhD
  • General Counsel, Interim Chief Executive Officer and President
  • 4.79M
  • Jean-Marc Bellemin
  • Chief Financial Officer and Principal Accounting Officer
  • 1.71M
  • Dr. Igor P. Bilinsky, PhD
  • Chief Operating Officer
  • 1.59M
  • Dr. Friedrich Graf Finckenstein
  • Chief Medical Officer
  • 1.77M
  • Dr. Iain D. Dukes, D.Phil.
  • Chairman of the Board
  • 933.48K
  • Wendy L. Yarno, M.B.A.
  • Independent Director
  • 460.65K
  • Dr. Athena Countouriotis, M.D.
  • Independent Director
  • 489.99K
  • Wayne P. Rothbaum
  • Independent Director
  • 240.00K
  • Dr. Michael Weiser,M.D.,PhD
  • Independent Director
  • 744.99K
  • General Merrill A. McPeak
  • Independent Director
  • 500.75K
  • Ryan D. Maynard
  • Independent Director
  • 489.99K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data